ARESTIN Powder for solution for injection Ref.[10750] Active ingredients: Minocycline

Source: FDA, National Drug Code (US)  Revision Year: 2020 

2. Clinical Pharmacology

Mechanism of Action

The mechanism of action of ARESTIN as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis is unknown.

Microbiology

Minocycline, a member of the tetracycline class of antibiotics, has a broad spectrum of activity. It is bacteriostatic and exerts its antimicrobial activity by inhibiting protein synthesis. In vitro susceptibility testing has shown that the organisms Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum, Eikenella corrodens, and Actinobacillus actinomycetemcomitans, which are associated with periodontal disease, are susceptible to minocycline at concentrations of ≤8 mcg/mL; qualitative and quantitative changes in plaque microorganisms have not been demonstrated in subjects with periodontitis, using this product.

The emergence of minocycline-resistant bacteria in single-site plaque samples was studied in subjects before and after treatment with ARESTIN at 2 centers. There was a slight increase in the numbers of minocycline-resistant bacteria at the end of the 9-month study period; however, the number of subjects studied was small and the clinical significance of these findings is unknown.

The emergence of minocycline-resistant bacteria and changes in the presence of Candida albicans and Staphylococcus aureus in the gastrointestinal tract were studied in subjects treated with ARESTIN in one phase 3 study. No changes in the presence of minocycline-resistant bacteria or Candida albicans or Staphylococcus aureus were seen at the end of the 56-day study period.

Pharmacokinetics

In a pharmacokinetic study, 18 subjects (10 men and 8 women) with moderate to advanced chronic periodontitis were treated with a mean dose of 46.2 mg (25 to 112 unit doses) of ARESTIN. After fasting for at least 10 hours, subjects received subgingival application of ARESTIN (1 mg per treatment site) following scaling and root planing at a minimum of 30 sites on at least 8 teeth. Investigational drug was administered to all eligible sites ≥5 mm in probing depth. Mean dose normalized saliva AUC and Cmax were found to be approximately 125 and 1000 times higher than those of serum parameters, respectively.

6.6. Carcinogenesis, Mutagenesis, Impairment of Fertility

Dietary administration of minocycline in long-term tumorigenicity studies in rats resulted in evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. In addition, there has been evidence of oncogenic activity in rats in studies with a related antibiotic, oxytetracycline (i.e., adrenal and pituitary tumors). Minocycline demonstrated no potential to cause genetic toxicity in a battery of assays which included a bacterial reverse mutation assay (Ames test), an in vitro mammalian cell gene mutation test (L5178Y/TK +/- mouse lymphoma assay), an in vitro mammalian chromosome aberration test, and an in vivo micronucleus assay conducted in ICR mice.

Fertility and general reproduction studies have provided evidence that minocycline impairs fertility in male rats.

13. Clinical Studies

In 2 well-controlled, multicenter, investigator-blind, vehicle-controlled, parallel-design studies (3 arms), 748 subjects (study OPI-103A=368, study OPI-103B=380) with generalized moderate to advanced adult periodontitis characterized by a mean probing depth of 5.90 and 5.81 mm, respectively, were enrolled. Subjects received 1 of 3 treatments: (1) scaling and root planing (SRP), (2) SRP + vehicle (bioresorbable polymer, PGLA), and (3) SRP + ARESTIN. To qualify for the study, subjects were required to have 4 teeth with periodontal pockets of 6 to 9 mm that bled on probing. However, treatment was administered to all sites with mean probing depths of 5 mm or greater. Subjects studied were in good general health. Subjects with poor glycemic control or active infectious diseases were excluded from the studies. Retreatment occurred at 3 and 6 months after initial treatment, and any new site with pocket depth ≥5 mm also received treatment. Subjects treated with ARESTIN were found to have statistically significantly reduced probing pocket depth compared with those treated with SRP alone or SRP + vehicle at 9 months after initial treatment, as shown in Table 1.

Table 1. Probing Pocket Depth at Baseline and Change in Pocket Depth at 9 Months from 2 Multicenter US Clinical Trials:

TimeStudy OPI-103A
N=368
Study OPI-103B
N=380
 SRP
Alone
n=124
SRP +
Vehicle n=123
SRP +
ARESTIN n=121
SRP
Alone
n=126
SRP +
Vehicle n=126
SRP +
ARESTIN n=128
PD (mm) at Baseline
[Mean ± SE]
5.88
±0.04
5.91
±0.04
5.88
±0.04
5.79
±0.03
5.82
±0.04
5.81
±0.04
PD (mm) Change from Baseline at 9
Months [Mean ± SE]
-1.04
±0.07
-0.90
±0.54
-1.20*††
±0.07
-1.32
±0.07
-1.30
±0.07
-1.63**††
±0.07

SE = standard error; SRP = scaling and root planing; PD = pocket depth
Significantly different from SRP: *(P ≤0.05); **(P ≤0.001)
Significantly different from SRP + vehicle: ††(P ≤0.001)

In these 2 studies, an average of 29.5 (5-114), 31.7 (4-137), and 31 (5-108) sites were treated at baseline in the SRP alone, SRP + vehicle, and SRP + ARESTIN groups, respectively. When these studies are combined, the mean pocket depth change at 9 months was -1.18 mm, -1.10 mm, and -1.42 mm for SRP alone, SRP + vehicle, and SRP + ARESTIN, respectively.

Table 2. Numbers (Percentage) of Pockets Showing a Change of Pocket Depth ≥2 mm at 9 Months from 2 Multicenter US Clinical Trials:

 Study OPI-103AStudy OPI-103B
 SRP
Alone
SRP +
Vehicle
SRP + ARESTINSRP
Alone
SRP +
Vehicle
SRP +
ARESTIN
Pockets
≥2 mm (% of Total)
1046
(31.1%)
927
(25.7%)
1326
(36.5%)
1692
(42.2%)
1710
(40.0%)
2082
(51.0%)
Pockets
≥3 mm (% of Total)
417
(12.4%)
315
(8.7%)
548
(15.1%)
553
(13.8%)
524
(12.3%)
704
(17.3%)

SRP + ARESTIN resulted in a greater percentage of pockets showing a change of PD ≥2 mm and ≥3 mm compared to SRP alone at 9 months, as shown in Table 2.

Table 3. Mean Pocket Depth Changes (SE) in Subpopulations, Studies 103A and 103B Combined:

 SRP
Alone
SRP +
Vehicle
SRP +
ARESTIN
Smokers n=91
-0.96 (±0.09) mm
n=90
-0.98 (±0.07) mm
n=90
-1.24 (±0.09) mm**
Nonsmokers n=159
-1.31 (±0.06) mm
n=159
-1.17 (±0.07) mm
n=159
-1.53 (±0.06) mm**
Subjects >50 YOA n=21
-1.07 (±0.09) mm
n=81
-0.92 (±0.08) mm
n=107
-1.42 (±0.08) mm**
Subjects ≤50 YOA n=167
-1.24 (±0.06) mm
n=168
-1.19 (±0.06) mm
n=142
-1.43 (±0.07) mm*
Subjects with CV Disease n=36
-0.99 (±0.13) mm
n=29
-1.06 (±0.14) mm
n=36
-1.56 (±0.14) mm**
Subjects without CV Disease n=214
-1.22 (±0.06) mm
n=220
-1.11 (±0.05) mm
n=213
-1.40 (±0.06) mm**

SRP = scaling and root planing; YOA = years of age; CV = cardiovascular
* SRP vs SRP + ARESTIN P ≤0.05; **SRP vs SRP + ARESTIN P ≤0.001

In both studies, the following patient subgroups were prospectively analyzed: smokers, subjects over and under 50 years of age, and subjects with a previous history of cardiovascular disease. The results of the combined studies are presented in Table 3.

In smokers, the mean reduction in pocket depth at 9 months was less in all treatment groups than in nonsmokers, but the reduction in mean pocket depth at 9 months with SRP + ARESTIN was significantly greater than with SRP + vehicle or SRP alone.

Table 4. Mean Pocket Depth Change in Subjects with Mean Baseline PD ≥5 mm, ≥6 mm, and ≥7 mm at 9 Months from 2 Multicenter US Clinical Trials:

 Study OPI-103AStudy OPI-103B
Mean Baseline
Pocket Depth
SRP
Alone
SRP + VehicleSRP + ARESTINSRP
Alone
SRP + VehicleSRP + ARESTIN
≥5 mm
(n)
-1.04 mm
(124)
-0.90 mm
(123)
-1.20 mm*
(121)
-1.32 mm
(126)
-1.30 mm
(126)
-1.63 mm*
(128)
≥6 mm
(n)
-0.91 mm
(34)
-0.77 mm
(46)
-1.40 mm*
(45)
-1.33 mm
(37)
-1.46 mm
(40)
-1.69 mm*
(25)
≥7 mm
(n)
-1.10 mm
(4)
-0.46 mm
(5)
-1.91 mm
(3)
-1.72 mm
(3)
-1.11 mm
(3)
-2.84 mm
(2)

* Statistically significant comparison between SRP + ARESTIN and SRP alone

The combined data from these 2 studies also show that for pockets 5 mm to 7 mm at baseline, greater reductions in pocket depth occurred in pockets that were deeper at baseline.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.